Abstract
NT-proBNP is produced from both atria and ventricles and it is increased in patients with cardiac disease. NT-proBNP is also associated with cerebral small vessel disease(cSVD) but there are no studies that had carried out a systematic evaluation of cardiac function in this specific setting. We conducted a prospective observational study in 100 patients within 30 days after a recent lacunar infarct by means of brain MRI, 24 h ambulatory blood pressure monitoring, transthoracic echocardiography, and plasmatic NT-proBNP. Global cSVD burden was quantified using a validated visual score (0 to 4) and dichotomized into 2 groups (0–2 or 3–4). Age (73.8 vs 63.5 years) and NT-proBNP (156 vs 76 pg/ml) were increased in patients with SVD 3–4, while daytime augmentation index normalized for the heart rate of 75 bpm (AIx75) (22.5 vs 25.6%) was decreased. The proportion of patients with left atrial enlargement, left ventricular hypertrophy, or septal e′ velocity <7 cm/s was not different between both groups. NT-proBNP was increased in patients with left atrial enlargement (126 vs 88 pg/ml). In multivariate analysis, age (OR 1.129 CI 95% 1.054–1.209), daytime AIx75 (OR 0.91 CI 95% 0.84–0.987,) and NT-proBNP (OR 1.007 CI 95% 1.001-1.012,) were independently associated with cSVD score 3–4. In conclusion, as well as in other patients with cSVD we found an association between NT-proBNP and cSVD. This association was independent of cardiac function.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
Data from this study will be available from the corresponding author upon reasonable request.
References
Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12:822–38.
Staals J, Makin SDJ, Doubal FN, Dennis MS, Wardlaw JM. Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burden. Neurology. 2014;83:1228–34.
Wei W, Chen Y, Lei D, Zhang Y, Weng X, Zhou Y, et al. Plasma brain natriuretic peptide is a biomarker for screening ischemic cerebral small vessel disease in patients with hypertension. Medicine. 2018;97:e12088–6.
Vilar-Bergua A, Riba-Llena I, Penalba A, Cruz LM, Jiménez-Balado J, Montaner J, et al. N-terminal pro-brain natriuretic peptide and subclinical brain small vessel disease. Neurology. 2016;87:2533–9.
Roberts E, Ludman AJ, Dworzynski K, Al-Mohammad A, Cowie MR, McMurray JJV, et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. Br Med J. 2015;350:h910.
Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39:3021–104.
O’Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31:1731–68.
Parati G, Stergiou G, O’Brien E, Asmar R, Beilin L, Bilo G, et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32:1359–66.
Hametner B, Wassertheurer S, Kropf J, Mayer C, Eber B, Weber T. Oscillometric estimation of aortic pulse wave velocity. Blood Press Monit. 2013;18:173–6.
Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiog. 2016;29:277–314.
Roberto ML, Luigi PB, Victor M-A, Jonathan A, Anderson A, Laura E, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiog. 2015;28:1–39.e14. https://doi.org/10.1016/j.echo.2014.10.003.
Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal. Aging AJR. 1987;149:351–6.
Potter GM, Chappell FM, Morris Z, Wardlaw JM. Cerebral perivascular spaces visible on magnetic resonance imaging: development of a qualitative rating scale and its observer reliability. Cerebrovasc Dis. 2015;39:224–31.
Wilson D, Ambler G, Shakeshaft C, Brown MM, Charidimou A, Salman RA-S, et al. Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study. Lancet Neurol. 2018;17:539–47.
Tomita H, Metoki N, Saitoh G, Ashitate T, Echizen T, Katoh C, et al. Elevated plasma brain natriuretic peptide levels independent of heart disease in acute ischemic stroke: correlation with stroke severity. Hypertens Res. 2008;31:1695–702.
Mahinrad S, Bulk M, Velpen I, van der, Mahfouz A, Roon-Mom W, van, Fedarko N, et al. Natriuretic peptides in post-mortem brain tissue and cerebrospinal fluid of non-demented humans and Alzheimer’s disease patients. Front Neurosci. 2018;12:864.
Mahinrad S, Sabayan B, Garner CR, Lloyd‐Jones DM, Sorond FA. N‐terminal pro brain, N‐terminal pro atrial natriuretic peptides, and dynamic cerebral autoregulation. J Am Heart Assoc. 2020;9:e018203 https://doi.org/10.1161/JAHA.120.018203.
Fish-Trotter H, Ferguson JF, Patel N, Arora P, Allen NB, Bachmann KN, et al. Inflammation and circulating natriuretic peptide levels. Circulation Heart Fail. 2020;13:e006570 https://doi.org/10.1161/CIRCHEARTFAILURE.119.006570.
Chamorro A, Hallenbeck J. The Harms and benefits of inflammatory and immune responses in vascular disease. Stroke. 2006;37:291–3.
Rahsepar AA, Bluemke DA, Habibi M, Liu K, Kawel‐Boehm N, Ambale‐Venkatesh B, et al. Association of Pro‐B‐type natriuretic peptide with cardiac magnetic resonance–measured global and regional cardiac function and structure over 10 years: the MESA study. J Am Heart Assoc. 2021;10:e019243 https://doi.org/10.1161/JAHA.120.019243.
Porpáczy A, Nógrádi Á, Vértes V, Tőkés-Füzesi M, Czirják L, Komócsi A, et al. Left atrial stiffness is superior to volume and strain parameters in predicting elevated NT-proBNP levels in systemic sclerosis patients. Int J Cardiovasc Imaging. 2019;35:1795–802.
Huijben AMT, Mattace-Raso FUS, Deinum J, Lenders J, Meiracker AH, van den. Aortic augmentation index and pulse wave velocity in response to head-up tilting. J Hypertens. 2012;30:307–14.
Nakano T, Munakata A, Shimaura N, Asano K, Ohkuma H. Augmentation index is related to white matter lesions. Hypertens Res. 2012;35:729–32.
Thomas O, Cain J, Nasralla M, Jackson A. Aortic pulsatility propagates intracranially and correlates with dilated perivascular spaces and small vessel compliance. J Stroke Cerebrovasc Dis. 2019;28:1252–60.
Inkeri J, Tynjälä A, Forsblom C, Liebkind R, Tatlisumak T, Thorn LM et al. Carotid intima-media thickness and arterial stiffness in relation to cerebral small vessel disease in neurologically asymptomatic individuals with type 1 diabetes. Acta Diabetol. 2021;929–37. https://doi.org/10.1007/s00592-021-01678-x.
Papaioannou TG, Thymis J, Benas D, Triantafyllidi H, Kostelli G, Pavlidis G, et al. Measurement of central augmentation index by three different methods and techniques: agreement among arteriograph, complior, and Mobil‐O‐Graph devices. J Clin Hypertens. 2019;21:1386–92.
Acknowledgements
We thank CERCA Programme/Generalitat de Catalunya for institutional support. We thank Juan Carlos Calvo for his technical assistance.
Author contributions
MGC designed the study, included patients in the study, collected data, and drafted the manuscript. LM, MAF, JJM, SG, and CA included patients and collected data. CM and LC carried out neuroimaging evaluation. PB performed transthoracic echocardiography. ML drawn blood samples and performed ambulatory blood pressure monitoring. MMB performed the statistical analysis. PA carried out blood pressure assessment, analyzed ambulatory blood pressure monitoring, and drafted the manuscript. LM, MAF, JJM, SG, CA, and PB made a critical review of the manuscript.
Funding
This work was supported by a grant from the Fondo de Investigaciones Sanitarias of the Spanish Ministry of Health (PI17/1188). MGC is funded by the Department of Health of the Generalitat de Catalunya (grant SLT008/18/00032) by the call “Acció instrumental: Intensificació de professionals de la salut, modalitat de professionals sanitaris (infermeria i fisioteràpia)”
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethical approval
The study was approved by Bellvitge University Hospital clinical research ethics committee with protocol number PR134/17. Written informed consent was obtained from all participants. The investigation conforms to the principles outlined in the declaration of Helsinki.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Gómez-Choco, M., Mena, L., Font, M.À. et al. NT-proBNP, cerebral small vessel disease and cardiac function in patients with a recent lacunar infarct. J Hum Hypertens 37, 62–67 (2023). https://doi.org/10.1038/s41371-021-00648-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41371-021-00648-8